We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
ANGLEFDA approval awaited, LDT data expected H122
Allergy TherapeuticsCommercialising and developing a differentiated portfolio
NexstimAdmirable execution on 2021 strategic goals
AvactaAffiDX LFT sales paused to improve Omicron detection
AvactaConsumer testing CE mark received for AffiDX LFT
Futura MedicalManagement update details degree of 2021 progress
AvactaAVA6000 set to start US Phase I studies in early-2022
MaxCyteNkarta signs SPL to accelerate its NK cell therapies
Allergy TherapeuticsPositive top line G309 results for Grass MATA MPL
Redx PharmaR&D update: RXC004 and RXC007 in the spotlight